Escient Pharmaceuticals Initiates Clinical Proof-of-Concept Study of EP262
Escient Pharmaceuticals Initiates Clinical Proof-of-Concept Study of EP262, a First-in-Class Oral MRGPRX2 Antagonist, in Chronic Spontaneous Urticaria
Escient Pharmaceuticals Initiates Clinical Proof-of-Concept Study of EP262, a First-in-Class Oral MRGPRX2 Antagonist, in Chronic Inducible Urticaria
SAN DIEGO--(BUSINESS WIRE)--Escient Pharmaceuticals, a clinical-stage drug development company advancing novel small molecule therapeutics for systemic neuro-inflammatory disorders, today announced positive results from a Phase 1 first-in-human study of EP262, a potent, highly selective small molecule antagonist of MRGPRX2.
SAN DIEGO--(BUSINESS WIRE)--Escient Pharmaceuticals, a clinical-stage company advancing novel small molecule therapeutics for the potential treatment of a broad range of neurosensory-inflammatory disorders, today announced the presentation of preclinical data in multiple models of mast cell degranulation related to the company’s EP262 development program at the European Academy of Allergy and Clinical Immunology annual meeting being held in Hamburg, Germany, June 9-11, 2023.
Escient Pharmaceuticals Announces Presentation of Data Demonstrating Efficacy of EP262 in a Mouse Model of Atopic Dermatitis at the American Academy of Dermatology Annual Meeting
Escient Pharmaceuticals Announces Oral Presentation of Data Highlighting the Preclinical Pharmacology of EP262 at the American Academy of Allergy, Asthma and Immunology Annual Meeting
The US Food and Drug Administration (FDA) has cleared Escient Pharmaceuticals’ investigational new drug (IND) application to commence a Phase I first-in-human trial of EP262 for mast cell mediated disorders.
Escient Pharmaceuticals Announces IND Clearance by FDA to Start Phase 1 Study of EP262, a First-in-Class Oral MRGPRX2 Antagonist for Mast Cell Mediated Disorders
Escient Pharmaceuticals Announces Oral Presentation of Data Highlighting the Preclinical Development of EP262 at the 6th GA2LEN Global Urticaria Forum